Vaginal birth not achieved in 48 to 72 h · patients with induction of labour at term
1 finding from 1 review
Serious maternal morbidity or death · women requiring induction of labour
1 finding from 1 review
Admission to neonatal intensive care unit · women requiring induction of labour
Vaginal misoprostol showed no clear difference in neonatal intensive care unit admission compared with placebo (low certainty).
1 finding from 1 review
Uterine hyperstimulation (fetal heart rate changes unclear) · patients with induction of labour at term
Vaginal PGE₂ showed no clear difference in uterine hyperstimulation (fetal heart rate changes unclear) compared with placebo or expectant management (low certainty).
1 finding from 1 review
Caesarean section · patients with induction of labour at term
Vaginal PGE₂ showed no clear difference in caesarean section compared with placebo or expectant management (low certainty).
1 finding from 1 review
Neonatal death or serious neonatal perinatal morbidity · patients with induction of labour at term
1 finding from 1 review
Serious maternal morbidity or death · patients with induction of labour at term
1 finding from 1 review
Admission to neonatal intensive care unit · patients with induction of labour at term
Vaginal PGE₂ showed no clear difference in neonatal intensive care unit admission compared with placebo or expectant management (low certainty).
1 finding from 1 review
Vaginal delivery not achieved within 24 hours · women requiring induction of labour
1 finding from 1 review
Vaginal birth not achieved in 48 to 72 h · women requiring induction of labour
Intracervical PGE₂ showed no clear difference in vaginal birth not achieved in 48 to 72 h compared with placebo (low certainty).
1 finding from 1 review
Pain duration (mean pain duration, assessed at 4 weeks) · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain duration (mean pain duration, assessed at 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain improvement (clinician judged, assessed at 2 weeks) · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain improvement (clinician judged, assessed at 2 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain episodes · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain frequency (episodes of pain in 4 weeks, assessed after 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain improvement (self reported response to treatment, assessed at 4 weeks) · Children with recurrent abdominal pain
Antispasmodics showed no clear difference in pain improvement (self reported response to treatment, assessed at 4… compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes mortality compared with placebo (very low certainty).
1 finding from 1 review
Cholecystectomy · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary sclerosing cholangitis
1 finding from 1 review